Trice Medical Achieves CE Mark and Health Canada Approval for Mi-Eye 2™, Performs First Cases in Toronto and the UK
Trice Medical completes its first successful case performed in the United Kingdom, after receiving CE Mark of approval in Europe for the mi-eye 2™, as well as entry into Health Canada.
The early success of Trice Medical’s mi-eye 2, which was launched in the U.S. in 2017, has captured the attention of medical professionals who are embracing the technology as a new diagnostic modality. After the first year of commercial launch, the mi-eye is currently being used by over 200 institutions across the states. The disposable needle embedded with a wide-angle camera lens enables physicians to diagnose joint injuries right in their clinic, and provide their patients with immediate answers to the cause of their pain.
For more click here.